search
Back to results

Digital Health Intervention for Caregivers Emotional and Self-management Support of Children With Type 1 Diabetes (CARING T1D)

Primary Purpose

Diabetes Mellitus, Type 1

Status
Recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Adhera® Caring digital intervention for Type 1 Diabetes
Sponsored by
Adhera Health, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Diabetes Mellitus, Type 1 focused on measuring Type 1 Diabetes, mhealth, caregiver, emotional health, behavioral intervention

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Caregiver of patients with type 1 diabetes under 18 years of age.
  • Patient's debut of type 1 diabetes at least 3 months prior to the start of the study.
  • Patients with continuous glucose monitoring.
  • Participants with children undergoing insulin treatments (multiple dose insulin or continuous subcutaneous insulin infusion)
  • Participants administering insulin treatment to their children
  • Users of smartphone whose children are treated with type 1 diabetes treatment for approved indications in Spain.
  • Participants must agree on sharing data on continuous glucose monitoring data of their treated children.
  • Participants must sign an informed consent
  • Participants must be willing to and install the mobile solution of the study.

Exclusion Criteria:

  • Candidates without a smartphone or not being able to interact with it.
  • Only one legal guardian per child can participate in the study.
  • Participants of SS1 will not take part in SS2.

Sites / Locations

  • Hospital Miguel ServetRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Qualitative sub-study 1 group

Quantitative sub-study 2 group

Arm Description

One group of caregivers (n = 20) will engage with the digital health solution during 1 month.

A different group of caregivers (n = 80) will engage with the digital health solution during 3 months.

Outcomes

Primary Outcome Measures

Sub-study 1: Qualitative data of psychological burdens experienced as caregivers of children with type 1 diabetes and barriers/facilitators for adopting the digital health solution
A semi-structured interview based on a mental health and technology acceptance theoretical framework has been specifically designed for this purpose.
Sub-study 2: Changes on caregiver's positive mood
Positive subscale of the Positive and Negative Affect Scale (PANAS). Scores can range from 10-50 for both the Positive and Negative Affect with the lower scores representing lower levels of Positive/Negative Affect and higher scores representing higher levels of Positive/Negative Affect.

Secondary Outcome Measures

Emotional outcome: Changes on caregiver's distress
Distress assessed with the depression, anxiety, and stress scale (DASS-21). DASS-21 is a self-report questionnaire consisting of 21 items, 7 items per subscale: depression, anxiety and stress. Patients are asked to score every item on a scale from 0 (did not apply to me at all) to 3 (applied to me very much). Sum scores are computed by adding up the scores on the items per (sub)scale and multiplying them by a factor 2. Sum scores for the total DASS-total scale thus range between 0 and 120, and those for each of the subscales may range between 0 and 42. Cut-off scores of 60 and 21 are used for the total DASS score and for the subscales respectively. Scores ≥60 (for DASS-total) and ≥21 (for the depression subscale) are labeled as "high" or "severe".
Emotional outcome: Changes on caregiver's general wellbeing
Assessed with the short form of the Mental Health Continuum - short form questionnaire (MHC-SF). Total sum scores on the MHC-SF can range from 0 to 70, with higher scores indicating higher levels of well-being.
Emotional outcome: Changes on caregiver's perceived self-efficacy
Perceived self-efficacy assessment with the General Self-Efficacy Scale (GSE), the total score ranges between 10 and 40, with a higher score indicating more self-efficacy.
Health-related Quality of Life (HrQoL): Changes on the child's HRQoL
Children HRQoL assessment with KIDSCREEN-10 index answered by the caregiver as a proxy. The scores range between 10 and 50, and are linearly converted into 0-100 scale in which higher scores represent better quality of life.
Life-style outcome: Adherence to Mediterranean diet
Assessed with the KIDMED questionnaire. This questionnaire consists of 16 questions, where negative answers are scored with 0, while affirmative answers are scored with +1/-1 depending on their positive or negative connotation.
Life-style outcome: physical activity (APALQ)
Physical activity assessed with Assessment Physical Activity Levels Questionnaire (APALQ). It is a self-administered questionnaire with 5 items scored 1 to 4/5, in which the sum of the answers classifies the global score in 3 categories: sedentary (5 to 10), moderately active (11-16), very active (+17).
Knowledge of the disease and its treatment.
Medical checking questions related to the disease, its treatment and if the patients are following the multiple doses of insulin (MDI) or the continuous subcutaneous insulin infusion (CSII) treatment.
Behavioral outcome: objectively measured children's metabolic control to the treatment
Assessed from the sensor used via glucose monitoring
Behavioral outcome: Usability
mHealth solution usability assessed with the System Usability Scale (SUS) questionnaire. SUS can range between 0 and 100 scores, with higher values representing higher usability.

Full Information

First Posted
July 28, 2022
Last Updated
June 14, 2023
Sponsor
Adhera Health, Inc.
Collaborators
Hospital Miguel Servet, Novo Nordisk A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT05483803
Brief Title
Digital Health Intervention for Caregivers Emotional and Self-management Support of Children With Type 1 Diabetes
Acronym
CARING T1D
Official Title
CARING: Feasibility Study of Digital Health for Caregivers Emotional and Self-management Support of Children With Type 1 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 1, 2022 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Adhera Health, Inc.
Collaborators
Hospital Miguel Servet, Novo Nordisk A/S

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This feasibility study builds upon mental health and technology acceptance theoretical frameworks. It seeks to examine potentials of a mobile-based novel digital health solution based on emotional and behavioral change techniques, to provide emotional and self-management tailored support to caregivers of children with type I diabetes (T1D). The digital health program, called Adhera® Caring, is designed to be used for approximately 3 months. The study will enroll 100 participants (20 in sub-study 1 and 80 in sub-study 2) who are caregivers of children with type 1 diabetes. There will be a nurse coaching the participants by providing support related to their emotional wellbeing via the mobile solution.
Detailed Description
Objectives: Primary objective 1. To gather qualitative and quantitative information enabling to better understand psychological burdens that caregivers of children with type 1 diabetes and perceived barriers/facilitators for adoption of a digital health solution. Primary objective 2. To assess positive mood states of caregivers of type 1 diabetes patients as an indicator of emotional wellbeing related to the use of the digital health solution. This is a prospective mixed-methods (qualitative-quantitative) exploratory study composed of two sub-studies: Qualitative sub-study 1 (SS1): One group of caregivers (n = 20) will engage with the digital health solution for 1 month. Subsequently, an individual semi-structured interview with each of the participants and a usability questionnaire will proceed to gather user experience qualitative information. Quantitative sub-study 2 (SS2): A different group of caregivers (n = 80) will engage with the digital health solution for 3 months. As elaborated in the following sections, a quantitative approach will be adopted to assess different emotional and behavioral parameters before and after engaging with the digital health solution (pre-post design).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 1
Keywords
Type 1 Diabetes, mhealth, caregiver, emotional health, behavioral intervention

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
Participants will be enrolled in two sub-studies. Participants in sub-study 1 will be enrolled in an intervention for 1 month. After sub-study 1 completion a new group of participants will be enrolled in the sub-study 2 for the intervention lasting 3 months.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Qualitative sub-study 1 group
Arm Type
Experimental
Arm Description
One group of caregivers (n = 20) will engage with the digital health solution during 1 month.
Arm Title
Quantitative sub-study 2 group
Arm Type
Experimental
Arm Description
A different group of caregivers (n = 80) will engage with the digital health solution during 3 months.
Intervention Type
Behavioral
Intervention Name(s)
Adhera® Caring digital intervention for Type 1 Diabetes
Intervention Description
The Adhera® Caring is a mobile based personalized digital intervention for caregivers, lasting for 1 or 3 months (depending on the sub-study).
Primary Outcome Measure Information:
Title
Sub-study 1: Qualitative data of psychological burdens experienced as caregivers of children with type 1 diabetes and barriers/facilitators for adopting the digital health solution
Description
A semi-structured interview based on a mental health and technology acceptance theoretical framework has been specifically designed for this purpose.
Time Frame
1 Month
Title
Sub-study 2: Changes on caregiver's positive mood
Description
Positive subscale of the Positive and Negative Affect Scale (PANAS). Scores can range from 10-50 for both the Positive and Negative Affect with the lower scores representing lower levels of Positive/Negative Affect and higher scores representing higher levels of Positive/Negative Affect.
Time Frame
3 Months
Secondary Outcome Measure Information:
Title
Emotional outcome: Changes on caregiver's distress
Description
Distress assessed with the depression, anxiety, and stress scale (DASS-21). DASS-21 is a self-report questionnaire consisting of 21 items, 7 items per subscale: depression, anxiety and stress. Patients are asked to score every item on a scale from 0 (did not apply to me at all) to 3 (applied to me very much). Sum scores are computed by adding up the scores on the items per (sub)scale and multiplying them by a factor 2. Sum scores for the total DASS-total scale thus range between 0 and 120, and those for each of the subscales may range between 0 and 42. Cut-off scores of 60 and 21 are used for the total DASS score and for the subscales respectively. Scores ≥60 (for DASS-total) and ≥21 (for the depression subscale) are labeled as "high" or "severe".
Time Frame
Baseline up to week 12
Title
Emotional outcome: Changes on caregiver's general wellbeing
Description
Assessed with the short form of the Mental Health Continuum - short form questionnaire (MHC-SF). Total sum scores on the MHC-SF can range from 0 to 70, with higher scores indicating higher levels of well-being.
Time Frame
Baseline up to week 12
Title
Emotional outcome: Changes on caregiver's perceived self-efficacy
Description
Perceived self-efficacy assessment with the General Self-Efficacy Scale (GSE), the total score ranges between 10 and 40, with a higher score indicating more self-efficacy.
Time Frame
Baseline up to week 12
Title
Health-related Quality of Life (HrQoL): Changes on the child's HRQoL
Description
Children HRQoL assessment with KIDSCREEN-10 index answered by the caregiver as a proxy. The scores range between 10 and 50, and are linearly converted into 0-100 scale in which higher scores represent better quality of life.
Time Frame
Baseline up to week 12
Title
Life-style outcome: Adherence to Mediterranean diet
Description
Assessed with the KIDMED questionnaire. This questionnaire consists of 16 questions, where negative answers are scored with 0, while affirmative answers are scored with +1/-1 depending on their positive or negative connotation.
Time Frame
Baseline up to week 12
Title
Life-style outcome: physical activity (APALQ)
Description
Physical activity assessed with Assessment Physical Activity Levels Questionnaire (APALQ). It is a self-administered questionnaire with 5 items scored 1 to 4/5, in which the sum of the answers classifies the global score in 3 categories: sedentary (5 to 10), moderately active (11-16), very active (+17).
Time Frame
Baseline up to week 12
Title
Knowledge of the disease and its treatment.
Description
Medical checking questions related to the disease, its treatment and if the patients are following the multiple doses of insulin (MDI) or the continuous subcutaneous insulin infusion (CSII) treatment.
Time Frame
Baseline up to week 12
Title
Behavioral outcome: objectively measured children's metabolic control to the treatment
Description
Assessed from the sensor used via glucose monitoring
Time Frame
Baseline up to week 12
Title
Behavioral outcome: Usability
Description
mHealth solution usability assessed with the System Usability Scale (SUS) questionnaire. SUS can range between 0 and 100 scores, with higher values representing higher usability.
Time Frame
At week 4 (sub-study 1) or week 12 (sub-study 2)

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Caregiver of patients with type 1 diabetes under 18 years of age. Patient's debut of type 1 diabetes at least 3 months prior to the start of the study. Patients with continuous glucose monitoring. Participants with children undergoing insulin treatments (multiple dose insulin or continuous subcutaneous insulin infusion) Participants administering insulin treatment to their children Users of smartphone whose children are treated with type 1 diabetes treatment for approved indications in Spain. Participants must agree on sharing data on continuous glucose monitoring data of their treated children. Participants must sign an informed consent Participants must be willing to and install the mobile solution of the study. Exclusion Criteria: Candidates without a smartphone or not being able to interact with it. Only one legal guardian per child can participate in the study. Participants of SS1 will not take part in SS2.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Luis Fernandez Luque, PhD
Phone
+34 717702622
Email
luis@adherahealth.com
First Name & Middle Initial & Last Name or Official Title & Degree
Julia Lopez Guimet, PhD
Email
jlopez@adherahealth.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Antonio de Arriba Muñoz, MD, PhD
Organizational Affiliation
Unidad de Endocrinología Pediátrica, Hospital Miguel Servet
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Luis Fernandez Luque, PhD
Organizational Affiliation
Adhera Health, Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Miguel Servet
City
Zaragoza
State/Province
Aragon
ZIP/Postal Code
50009
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Antonio de Arriba Muñoz, MD, PhD
Email
adearriba@salud.aragon.es

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32338624
Citation
Carrasco-Hernandez L, Jodar-Sanchez F, Nunez-Benjumea F, Moreno Conde J, Mesa Gonzalez M, Civit-Balcells A, Hors-Fraile S, Parra-Calderon CL, Bamidis PD, Ortega-Ruiz F. A Mobile Health Solution Complementing Psychopharmacology-Supported Smoking Cessation: Randomized Controlled Trial. JMIR Mhealth Uhealth. 2020 Apr 27;8(4):e17530. doi: 10.2196/17530.
Results Reference
background

Learn more about this trial

Digital Health Intervention for Caregivers Emotional and Self-management Support of Children With Type 1 Diabetes

We'll reach out to this number within 24 hrs